Fever Clinical Trial
— TRActionOfficial title:
Universal Versus Conditional Three-day Follow-up Visit for Children With Unclassified Fever at the Community Level: A Study to be Conducted in Ethiopia
Verified date | January 2018 |
Source | Malaria Consortium |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fevers in childhood are common and usually self-resolve. In sub-Saharan Africa, when a febrile child presents to a community health worker (CHW), the child is assessed for malaria, pneumonia, and diarrhea, and other danger signs, according to WHO guidelines for integrated Community Case Management (iCCM) of childhood illnesses. In the cases where 1) there are no danger signs present, and 2) malaria, pneumonia, and diarrhea have been ruled out, the World Health Organization (WHO) recommends that all children be reassessed in 3 days. It is hypothesized that health outcomes for these cases will be equivalent if the CHW advises to come back in 3 days only if symptoms have not resolved. In order to assess this hypothesis, a two-arm cluster-randomized, community-based non-inferiority trial in Southern Nations, Nationalities and People's Regional State (SNNPR) in Southwest Ethiopia will be conducted to assess the non-inferiority of CHW-advised systematic follow-up on day 3 compared to conditional follow-up for non-severe febrile illness in children age 2 to 59 months, in which no cause of fever can be identified and where danger signs are absent.
Status | Completed |
Enrollment | 4179 |
Est. completion date | May 1, 2017 |
Est. primary completion date | November 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Months to 59 Months |
Eligibility |
Inclusion Criteria: - Non-severe febrile illness that is classified by HEW as unspecific fever Exclusion Criteria: - Malaria, pneumonia, diarrhoea diagnosis - Symptoms requiring referral |
Country | Name | City | State |
---|---|---|---|
Ethiopia | Ethiopia | Hawassa | Southern Nations, Nationalities, And Peoples' Region |
Lead Sponsor | Collaborator |
---|---|
Malaria Consortium | Centers for Disease Control and Prevention, Karolinska Institutet |
Ethiopia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Caregiver and HEW acceptability of systematic and conditional follow-up | The acceptability of caregivers and HEW towards the two types of follow-up recommendations | Day 0-28 | |
Primary | Treatment failure | Proportion of children with non-severe febrile illness who, after initial evaluation by a HEW using iCCM algorithm, are not treated for malaria, pneumonia, or diarrhea and who subsequently decline clinically (defined as death, hospitalization, or the development of one or more danger signs). | Day 7 | |
Secondary | Illness classification among children with unresolved illness | Descriptive statistics of the symptoms and signs in those children with unresolved illness at Day 7 in each arm, as identified by clinically trained research assistants. | Day 7 | |
Secondary | Proportion of caregivers who present to HEWs for the follow-up visit on Day 3 | Proportion of caregivers who present for the follow-up visit on Day 3 in the 'systematic visit arm' | Day 3 | |
Secondary | Proportion of caregivers who spontaneously re-present to HEWs | Proportion of caregivers who spontaneously re-present to HEWs for persistence or worsening of symptoms in the 'conditional visit arm' | Day 0-7 | |
Secondary | Secondary treatment | Proportion of children receiving secondary treatment (antimicrobial medicines prescribed during visits to any providers after initial presentation to HEWs) in each arm | Day 0-7 | |
Secondary | Hospital admission rate | Rate of hospital admission due to illness up to Day 7 in each arm | Day 0-7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03706599 -
Fever Infants and Therapeutic Education in Emergency Department
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Not yet recruiting |
NCT01782183 -
Thermographic Characteristics of Sore Throat by Thermographic Camera
|
N/A | |
Withdrawn |
NCT00800696 -
Preventive Oral Care
|
N/A | |
Completed |
NCT02689193 -
IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres
|
||
Completed |
NCT02212990 -
The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine
|
N/A | |
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01869699 -
Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults
|
Phase 4 | |
Completed |
NCT01194557 -
Introducing Rapid Diagnostic Tests Into the Private Health Sector
|
N/A | |
Completed |
NCT01559675 -
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
|
N/A | |
Completed |
NCT00969176 -
Pharmacokinetics, -Dynamics and Safety of Intravenous Paracetamol in Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00940654 -
The Fever and Antipyretic in Critically Illness Evaluation Study
|
N/A | |
Recruiting |
NCT00729976 -
Oral Versus Rectal Ibuprofen for Fever in Young Children - a Randomized Control Study.
|
Phase 4 | |
Recruiting |
NCT00389272 -
Adding a Second Drug for Febrile Children Treated With Acetaminophen
|
N/A | |
Completed |
NCT00257790 -
The Tobramycin Study
|
Phase 4 | |
Recruiting |
NCT05033613 -
Home Blood Pressure Monitoring Before and After COVID-19 Vaccination in Patients at High Risk of Cardiovascular Disease
|
||
Completed |
NCT02595827 -
Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo
|
Phase 3 | |
Recruiting |
NCT06061575 -
Comparison of the Efficacy of Paracetamol and Ibuprofen in the Management of Fever in Sepsis Patients
|
Phase 4 | |
Recruiting |
NCT06038617 -
Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children
|
Phase 4 |